Literature DB >> 17017502

The discovery of dopamine deficiency in the parkinsonian brain.

O Hornykiewicz1.   

Abstract

This article gives a short historical account of the events and circumstances that led to the discovery of the occurrence of dopamine (DA) in the brain and its deficiency in Parkinson's disease (PD). Some important consequences, for both the basic science and the patient, of the work on DA in the PD brain are also highlighted.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17017502     DOI： 10.1007/978-3-211-45295-0_3

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN： 0303-6995


  51 in total

1.  The subthalamic nucleus is one of multiple innervation sites for long-range corticofugal axons: a single-axon tracing study in the rat.

Authors:  Takako Kita; Hitoshi Kita
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

2.  Effects of the beta-adrenergic receptor antagonist Propranolol on dyskinesia and L-DOPA-induced striatal DA efflux in the hemi-parkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Christopher J Barnum; Jessica A George; Margaret A Surrena; Christopher Bishop
Journal:  J Neurochem       Date:  2015-04-27       Impact factor: 5.372

Review 3.  Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

Authors:  Christopher L German; Michelle G Baladi; Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

4.  Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease.

Authors:  Willyan Franco Hilario; Alice Laschuk Herlinger; Lorena Bianchine Areal; Lívia Silveira de Moraes; Tamara Andrea Alarcon Ferreira; Tassiane Emanuelle Servane Andrade; Cristina Martins-Silva; Rita Gomes Wanderley Pires
Journal:  J Mol Neurosci       Date:  2016-09-22       Impact factor: 3.444

5.  High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson's disease.

Authors:  Aslıhan Baran; Mahmut Bulut; Mehmet Cemal Kaya; Özlem Demirpençe; Bünyamin Sevim; Eşref Akıl; Sefer Varol
Journal:  Neurol Sci       Date:  2018-10-23       Impact factor: 3.307

6.  NMR-Based Metabolomics Reveal a Recovery from Metabolic Changes in the Striatum of 6-OHDA-Induced Rats Treated with Basic Fibroblast Growth Factor.

Authors:  Hong Zheng; Liangcai Zhao; Huanhuan Xia; Cuicui Xu; Dan Wang; Kun Liu; Li Lin; Xiaokun Li; Zhihan Yan; Hongchang Gao
Journal:  Mol Neurobiol       Date:  2015-12-09       Impact factor: 5.590

Review 7.  Manganese and Parkinson's disease: a critical review and new findings.

Authors:  Tomás R Guilarte
Journal:  Environ Health Perspect       Date:  2010-04-19       Impact factor: 9.031

8.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

9.  D2-like dopamine receptor-mediated modulation of activity-dependent plasticity at GABAergic synapses in the subthalamic nucleus.

Authors:  Jérôme Baufreton; Mark D Bevan
Journal:  J Physiol       Date:  2008-02-21       Impact factor: 5.182

10.  Sparse but selective and potent synaptic transmission from the globus pallidus to the subthalamic nucleus.

Authors:  Jérôme Baufreton; Erin Kirkham; Jeremy F Atherton; Ariane Menard; Peter J Magill; J Paul Bolam; Mark D Bevan
Journal:  J Neurophysiol       Date:  2009-05-20       Impact factor: 2.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.